Principal Investigator/Program Director (Last, first, middle):BIOGRAPHICAL SKETCH
Provide the following information for the key personnel in the order listed for Form Page 2.
Follow the sample format on preceding page for each person. DO NOT EXCEED FOUR PAGES.
Medical Director, Portuguese Mental Health Clinic; Director, Depression and Anxiety Disorders Research Program, Cambridge Health Alliance, Harvard Medical School
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
Federal University of Rio de Janeiro, Brazil
Rochester, MN Massachusetts General Hospital, Boston, MA
Massachusetts General Hospital, Boston, MA
A. Positions and Honors. Positions and Employment 2003- Medical Director, Portuguese Mental Health Clinic, Cambridge Health Alliance 2003- Director, Depression and Anxiety Disorders Research Program, Cambridge Health Alliance 2003- Instructor in Psychiatry, Harvard Medical School Other Experience and Professional Memberships 2001- 2003 Investigator, Anxiety Disorders Program, Department of Psychiatry, MGH. 1997-1998 Investigator, Anxiety and Depression Research Program, Institute of Psychiatry/UFRJ. Honors 1993-1994 National Council for Scientific Research (CNPq) Award 1994
Teacher Assistant/UFRJ Scholarship, Department of Pathology
County Health General Office, Academic Award
1995-1996 Teacher Assistant/UFRJ Scholarship, Department of Psychiatry 1999-2000 Howard P. Rome Scholarly Writing Award, Mayo Clinic 2000
2000-2001 Howard P. Rome Scientific Writing Award, Mayo Clinic 2002 Society of Biological Psychiatry Fellowship Award 2002 APA/APIRE Minority Fellowship Program 2002 Anxiety Disorders Association of America (ADAA) Travel Award 2002 NIMH/NCDEU New Investigator’s Program Award
B. Peer-Reviewed Publications.
1. Kinrys G, Nardi AE et al: Valproic acid in the treatment of Panic disorder. Brazilian Journal of
Continuation Format Page
Use ½-inch MARGINS. Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b.
Principal Investigator/Program Director (Last, first, middle):
2. Kinrys G, Nardi AE et al: Valproic acid: Review of its pharmacological properties. Brazilian Journal of
3. Mendlowicz M, Kinrys G, et al: Inefficacy of valproate in the treatment of Social phobia. Brazilian
Journal of Psychiatry, 44(12): 643-645, 1995.
4. Marques C, Nardi AE, Kinrys G et al: Acute dystonic reaction with fluoxetine: case report. Brazilian
Journal of Psychiatry 45(1): 51-54, 1996.
5. Marques C, Nardi AE, Kinrys G et al: SSRIs and weight gain. Brazilian Journal of Psychiatry 45(2): 111-
6. Nardi AE, Andrade Y, Kinrys G et al: Generalized anxiety disorder: theoretical and diagnostic principles.
Brazilian Journal of Psychiatry 45(3): 173-178, 1996.
7. Nardi AE, Andrade Y, Kinrys G et al: Generalized anxiety disorder: clinical cases and treatment.
Brazilian Journal of Psychiatry 45(4): 237-240, 1996.
8. Maurat A, Nardi AE, Kinrys G et al: Biological aspects of posttraumatic stress. Brazilian Journal of
9. Valença A, Andrade Y, Kinrys G et al: Panic disorder and respiration. Brazilian Journal of Psychiatry
10. Kinrys G, Bostwick JM, Steroid-responsive delirium associated with thyroiditis. Psychosomatics,
11. Simon NM, Korbly NB, Worthington JW, Kinrys G, and Pollack MH. Citalopram for Social Anxiety
Disorder: an Open-Label Pilot Study in Refractory and Non-Refractory Patients. CNS Spectrums 2002; 7(9): 655-662.
12. Kinrys G, Pollack MH, Simon N, Worthington JW, Nardi AE, Versiani M: Valproic acid for the treatment
of Social Anxiety Disorder. International Clinical Psychopharmacology 2003;18(3):169-72.
13. Simon NM, Emanuel N, Ballenger J, Worthington JJ, Kinrys G, Korbly NB, Farach FJ, and Pollack MH.
Bupropion Sustained Release for Panic Disorder. Psychopharmacology Bulletin, 2003; 37(4):66-72.
14. Simon NM, Worthington JW, Reese H, Kinrys G, Pollack MH. An Open-Label Study of Levetiracetam
for the Treatment of Social Anxiety Disorder. Journal of Clinical Psychiatry, 2004; 65(9):1219-22.
15. Kinrys G, Wygant L, Nery F, Pardo T, Melo M. Tiagabine for Treatment Refractory Social Anxiety
Disorder. Psychiatry Research. In Press.
16. Worthington JW, Kinrys G, Wygant L, Pollack M. Aripiprazole as an Augmentor in Refractory
Depression and Anxiety. International Clinical Psychopharmacology 2005 Jan; 20(1):9-11.
17. Kinrys G, Wygant LE. [Anxiety disorders in women: does gender matter to treatment?] Rev Bras
Psiquiatr. 2005 Oct;27 Suppl 2:S43-50. Epub 2005 Nov 10.
Continuation Format Page
Use ½-inch MARGINS. Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b.
Principal Investigator/Program Director (Last, first, middle):
18. Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, Fava M, Nierenberg AA.
Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry. 2005 Oct;66(10):1326-30.
19. Kinrys G, Wygant LE. Anticonvulsants in anxiety disorders. Curr Psychiatry Rep. 2005 Aug;7(4):258-
20. Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, Pollack MH. An open-
label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006 Mar;67(3):381-5.
21. Papakostas GI, Worthington JJ 3rd, Iosifescu DV, Kinrys G, Burns AM, Fisher LB, Homberger CH,
Mischoulon D, Fava M. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety. 2006;23(3):178-81.
22. Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J.
Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006 Feb 1;59(3):211-5.
23. Kinrys G, Wygant LE, Pardo TB, Melo M.Levetiracetam for treatment-refractory posttraumatic stress
disorder. J Clin Psychiatry. 2006 Feb;67(2):211-4.
24. Kinrys G. Levetiracetam: A critical review of the literature. Expert Opinions Journal. July 2007. In press.
25. Kinrys G and Rothstein E. Antipsychotics for Treatment Refractory Anxiety: Clinical Use and
Applications. Psychiatric Times. July 2007. In press.
26. Kinrys G and Bianco R. Treatment Refractory Anxiety: Diagnosis and Treatment. Current Psychiatry.
27. Kinrys G, Vasconcelos DS, Nery F. Zonisamide for Treatment Refractory Anxiety. International Journal
28. Kinrys G, Worthington JW, Reese H, Simon NM, Doyle A, Melo M, Pollack MH. Levetiracetam for
Treatment Refractory Anxiety Disorders. J Clin Psychiatry. 2007 Jun;68(6):1326-30.
29. Fiszman A, Marques C, Mendlowicz M, Kinrys G, Figueira I. Treatment Refractory Posttraumatic
Stress Disorder. Revista Brasileira de Psiquiatria. July 2007. In press.
30. Pollack MH, Kinrys G, Krystal A et al. Evaluation of Eszopiclone and Escitalopram Oxalate Co-therapy
in Patients with Insomnia and Comorbid Generalized Anxiety Disorder. Archives of General Psychiatry. In press.
Continuation Format Page
Use ½-inch MARGINS. Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b.
Immunization Division, Texas Department of Health 1100 West 49th St., Austin, TX 78756 (800) 252-9152 (512) 458-7544 fax Pertussis Case Track Record FINAL STATUS : NETSS CASE # : Patient’s Name: ______________________________________________________ Reported By: ___________________________________________ Address: _________________________________________________________
DON ÁLVARO DE LUNA TRAGEDIA EN CUATRO ACTOS Por Santiago Sevilla Larrea INTRODUCCIÓN Las coplas del insigne poeta Don Jorge Manrique, coetáneo de los Reyes Católicos, nos plantean ciertas preguntas filosóficas que han quedado hasta ahora, por más de quinientos años, sin una respuesta dramática: “¿Qué se hizo el rey don Juan? Los Infantes de Aragón, ¿qué se hicieron? ¿q